Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytoplasmic linker protein 1 (CLIP1), also known as CLIP-170, is a member of the microtubule-plus-end-tracking proteins (+TIPs) that plays a fundamental role in regulating microtubule dynamics and linking cellular organelles to the cytoskeleton (UniProt: P30622). It facilitates the initiation of microtubule growth and is essential for the recruitment of the dynein-dynactin complex to microtubule ends, which is critical for retrograde transport and cell migration (PubMed: 10531020). During mitosis, CLIP1 is required for stable kinetochore-microtubule attachments and proper spindle assembly, ensuring the high fidelity of chromosome segregation (PubMed: 15632202). In clinical oncology, CLIP1 is recognized as a significant fusion partner for the Anaplastic Lymphoma Kinase (ALK) gene; the resulting CLIP1-ALK fusion acts as an oncogenic driver in non-small cell lung cancer (NSCLC) and is a validated target for ALK tyrosine kinase inhibitors (PubMed: 29330158). Beyond cancer, germline mutations in the CLIP1 gene have been identified as a cause of autosomal recessive primary microcephaly, underscoring its vital role in brain development and neuronal proliferation (PubMed: 25944325). While CLIP1 is not typically the primary target of small molecules, its involvement in microtubule stability makes it a key factor in determining cellular sensitivity to microtubule-targeting agents like taxanes.
Inhibition of the tyrosine kinase activity of CLIP1-ALK fusion proteins to disrupt oncogenic signaling pathways.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytoplasmic linker protein 1 (CLIP1).